Funding for this study was provided by Gilead Sciences ♦ Highly effective antiretroviral (ARV) therapies have transformed treatment of HIV patients from acute to chronic-care.
♦ HIV patients are living longer and treated earlier, resulting in increased exposure to ARV therapies.
♦ With increasing age and duration of HIV and treatment, comorbidities such as chronic kidney disease (CKD), cardiovascular disease (CVD), fractures, and neuropsychiatric disorders are increasing.
♦ E/C/F/TAF, a novel ARV approved by the US FDA and included in the DHHS list of recommended regimens, has demonstrated robust clinical efficacy with superior renal and bone safety profiles compared to recommended and alternative regimens.
♦ How the introduction of E/C/F/TAF may impact the health economics of HIV needs to be understood in balancing needs and costs of formulary decisions.
Figure 1. Model Structure
♦ To estimate the projected health economic impact of introducing E/C/F/TAF in treatmentnaïve (TN) and virally suppressed treatment-experienced (TE) HIV patients compared to current DHHS recommended and alternative regimens.
♦ The addition of E/C/F/TAF as a treatment option reduced comorbid events such as progression to CKD-III and CVD, and reduced switching to subsequent lines of therapy compared to current DHHS preferred and alternative regimens. ♦ As an alternative to FTC/TDF-based regimens, E/C/F/TAF reduced the rates of renal events from 25%-40% across all scenarios. E/C/F/TAF reduced the rates of CVD compared to ABC/3TC/DTG from 11%-25% across all the scenarios. ♦ Benefits of E/C/F/TAF on treatment failure, events, and persistence were comparable among Base Case, Low, and High Risk patient populations. ♦ As a result of improved outcomes, persistence, and reduced switching, E/C/F/TAF results in substantial pharmacy and medical cost savings for patients in all scenarios. ♦ ARV, pharmacy, and medical cost savings are achieved in year 1, with savings in each increasing each year in years 2 to 5 (data not shown). ♦ Virologic failure, switching due to treatment failure and events, and progression to CKDIII and CVD events are the major drivers to inferior and costly outcomes. E/C/F/TAF would bring both improved health outcomes and economic benefits to patients regardless of their underlying risk profiles. Figure 2 . ♦ Risk for fracture was estimated based upon World Health Organization FRAX equations. ♦ Inputs were drawn from published randomized controlled trials, reviews of the peerreviewed literature, and real-world database analyses. ♦ Data for virologic suppression rates were sourced from published, randomized controlled trials, and are summarized in Table 2 . Key: 3TC -lamivudine; ABC -abacavir; ATV/r -ritonavir-boosted atazanavir; DRV/r -ritonavir-boosted darunavir; DTG -dolutegravir; TAF -tenofovir alafenamide; EFV -efavirenz; FTC -emtricitabine; LPV/r -ritonavir-boosted lopinavir; RAL -raltegravir; RPV -rilpivirine; TDF -tenofovir disoproxil fumarate; TE -treatment-experienced; TE-RI -treatment experienced renal impaired; TN -treatment-naïve.
Objectives
• Tx Failure -Treatment Failure: Defined per trial protocol, including confirmed HIV-1 RNA >50 copies/mL, missing virologic data, or discontinuation.
• CKD-III -Chronic kidney disease, Stage 3: Defined as confirmed (>3 months apart) eGFR <60 mL/min/1.73 m2.
• ESRD -End stage renal disease: Chronic dialysis treatment or kidney transplant, ascertained by the United States Renal Data System.
• CVD -Cardiovascular disease: MI, stroke , invasive coronary artery procedure (CABG), or death related to coronary heart disease.
• AIDS -acquired immunodeficiency syndrome; HIV -human immunodeficiency virus.
• MOF-Major osteoporotic fracture: Defined as fracture of the hip, clinical spine, forearm, and proximal humerus Costs ♦ Costs were calculated for the entire patient population and on a per member per month (PMPM) basis over a 5-year period. ♦ Pharmacy and medical costs associated with HIV treatment as well as comorbid events and conditions were evaluated. ♦ Regimen costs were based on published, annual wholesale acquisition costs (WAC) as of February, 2016. ♦ Non-ARV costs including inpatient, outpatient, and pharmacy costs for renal, CVD, and fracture events, as well as medical costs associated with HIV, were derived from analyses of patients in the Truven MarketScan database and from the published literature (Solem, 2014, Taylor, 2011).
Figure 2. Event Risk Equations
♦ Estimated event rates depend upon the underlying baseline distribution of High, Medium, and Low patient risk groups. ♦ Base Case risk profile distribution was drawn from analyses of patients in the Quintiles Electronic Medical Records (EMR) database. ♦ Low and High Risk Scenario population distributions were estimated by shifting 10% of patients in each risk stratum to lower baseline risk categories (Low Risk Scenario) or 10% to higher baseline risk categories (High Risk Scenario). Distributions are shown in Figure 3 . Key: CKD-III -chronic kidney disease stage 3; CVD -cardiovascular disease; Fracture: major osteoporotic fracture; Tx Failure -treatment failure; NNT -number needed to treat with E/C/F/TAF to avoid one event; REF -reference product, NNT not calculated E -elvitegravir; C -cobicistat; F or FTC -emtricitabine; TAF -tenofovir alafenamide ; TDF -tenofovir disoproxil fumarate; 3TC -lamivudine; ABC -abacavir; DTG -dolutegravir ; EFV -efavirenz. 
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